GENERAL SERVICES ADMINISTRATION

Federal Property Resources Service

[Wildlife Order 158; 4-D-PA-712]

Union City Dam Project, French Creek, Waterford and Amity Townships, Erie County, PA; Conveyance of Property

Pursuant to section 2 of Pub. L. 537, 80th Congress, approved May 19, 1948 (16 U.S.C. 667c), notice is hereby given that:

1. By deed from the General Services Administration dated March 18, 1985, the property, consisting of 303.79 acres of unimproved land, known as the Union City Dam Project, Waterford and Amity Townships, Erie County, Pennsylvania (4-D-PA-712), has been transferred to the Pennsylvania Game Commission.

2. The above described property was conveyed for wildlife conservation in accordance with the provisions of section 1 of said Pub. L. 80-537 (16 U.S.C. 667b), as amended by Pub. L. 92-432.

Dated: May 8, 1985.

J. Wayne Kulig,

Acting Commissioner, Federal Property Resources Service.

[FR Doc. 85-11988 Filed 5-16-85; 8:45 am]

BILLING CODE 6820-96-M

Intent To Prepare a Supplemental EIS

The General Services Administration (GSA) will prepare a Supplemental Draft and Final Environmental Impact Statement on the proposed disposal of four parcels of land in Rhode Island. The four parcels are:

Hoskins Park Housing Area—86.68 acres of land with 102 buildings containing 333 housing units in North Kingstown,

Old Wickford—5.1 acres of level, vacant land in North Kingstown,

Naval Gardens Housing Area—14.3 acres of land with 16 buildings containing 119 housing units in Middletown, and

Gould Island (Portion)—22.02 acres of land and 8 buildings thereon.

The Supplemental EIS will contain site-specific information on each of these parcels and consider the impacts of reasonable reuse alternatives.

Two scoping meetings will be held for the identification of issues. One will be held on May 23, 1985, at 7:30 p.m., at the Davisville Middle School, North Kingstown, R.I., and the other on May 30, 1985, at 7:30 p.m., at the Middletown, R.I. Town Hall. Interested participants may register by mail or in person at the address below for an opportunity to make a presentation at either meeting. Presentations will be heard in the order of registration. Registrations will also be accepted in person at the meeting place prior to the start of the meeting.

Interested parties unable to attend either meeting may submit written suggestions on the scope of the EIS at the address below for a period of 30 days following publication of this notice.

Questions, comments, and requests for further information may be addressed to: Pasquale Vaccaro, Realty Officer, General Services Administration, 806 J.W. McCormick Post Office & Courthouse, Boston, Massachusetts 02109, Telephone: (617) 223-2651.

Dated: May 8, 1985.

J. Wayne Kulig,

Acting Commissioner, Federal Property Resources Service.

[FR Doc. 85-11989 Filed 5-16-85; 8:45 am]

BILLING CODE 6820-96-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Agency Forms Submitted to the Office of Management and Budget for Clearance

Each Friday the Department of Health and Human Services (HHS) publishes a list of information collection packages it has submitted to the Office of Management and Budget (OMB) for clearance in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). The following are those packages submitted to OMB since the last list was published on May 10, 1985.

Public Health Service

National Institutes of Health

Subject: Sister Chromatid Exchanges in the Lymphocytes of Smokers, Passive Smokers and Non-Smokers—New
Respondents: Individuals

Health Resources and Services Administration

Subject: Record of State and Local Action Under Section 1122 of the Social Security Act—Extension (0915-0055)
Respondents: Businesses

Office of the Assistant Secretary for Health

Subject: PHS Contractors Profile System—Extension (0937-0120)
Respondents: Small businesses
OMB Desk Officer: Fay S. Iudicello

Health Care Financing Administration

Subject: Medicaid Quality Control (MQC) Statistical Tables—Reinstatement (0938-0310)
Respondents: State/local governments
OMB Desk Officer: Fay S. Iudicello

Social Security Administration

Subject: National Reference Center User Survey—SSA 5039—New
Respondents: Individuals, states
Subject: Taxation of Benefits Questionnaire—SSA 5031—Revision (0960-0401)
Respondents: Individuals
Subject: State Agency Schedule for Equipment Purchases for SSA Disability Programs—SSA 871—Existing Collection
Respondents: State governments
OMB Desk Officer: Judy A. McIntosh.

Copies of the above information collection clearance packages can be obtained by calling the HHS Reports Clearance Officer on 205-245-6511.

Written comments and recommendations for the proposed information collections should be sent directly to the appropriate OMB Desk Officer designated above at the following address: OMB Reports Management Branch, New Executive Office Building, Room 3208, Washington, D.C. 20503. Attn: (name of OMB Desk Officer).

Dated: May 10, 1985.

Wallace O. Keene,

Acting Deputy Assistant Secretary for Management Analysis and Systems.

[FR Doc. 85-11869 Filed 5-16-85; 8:45 am]

BILLING CODE 4150-04-M

Advisory Committees; Meetings

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), announcement is made of the following National Advisory bodies scheduled to meet during the month of June 1985:

Name: Health Services Developmental Grants Review Subcommittee.

Date and time: June 11-12, 1985, 8:30 a.m.

Place: Hyatt Regency O'Hare, Pan Am A Room, 9300 West Bryn Mawr Avenue, Rosemont, Illinois 60018.

Open June 11, 8:30 a.m. to 9:30 a.m.

Closed for remainder of meeting.

Purpose: The Subcommittee is charged with the initial review of grant applications for Federal assistance in the program areas administered by the National Center for Health Services Research and Health Care Technology Assessment (NCHSR).

Agenda: The open session of the meeting of June 11 from 8:30 AM to 9:30 AM will be devoted to a business meeting covering administrative matters and reports. There will also be a presentation by the Director, NCHSR. During the closed sessions, the Subcommittee wil be reviewing research grant applications relating to the delivery, organization, and financing of health services. In accordance with the Federal Advisory Committee Act, Title 5, U.S. Code, Appendix 2 and Title 5, U.S. Code 552b(c)(6), the Assistant Secretary for Health has made a formal determination that these latter sessions will be closed because the discussions are likely to reveal personal information concerning individuals associated with the applications. This informtion is exempt from mandatory disclosure.

Anyone wishing to obtain a Roster of Members, Minutes of Meeting, or other relevant information should contact Mr. Hoke S. Glover, National Center for Health Services Research and Health Care Technology Assessment, Stop 152, Park Building, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone (301) 443–3091.

* * * * *

Name: Health Care Technology Study Section.

Date and time: June 11–12, 1985, 8:00 a.m.

Place: Hyatt Regency O'Hare, Ozark A Room, 9300 West Bryn Mawr Avenue, Rosemont, Illinois 60018.

Open June 11, 8:00 a.m. to 9:00 a.m.

Closed for remainder of meeting.

Purpose: The Committee is charged with the initial review of health research grant applications for Federal assistance in the program areas administered by the National Center for Health Services Research and Health Care Technology Assessment (NCHSR).

Agenda: The open session from 8:00 AM to 9:00 AM on June 11 will be devoted to a business meeting covering administrative matters and reports. There will also be a presentation by the Director, NCHSR. The closed portion of the meeting will be devoted to review of health services research grant applications relating to the delivery, organization, and financing of health services. In accordance with the Federal Advisory Committee Act, Title 5, U.S. Code, Appendix 2 and Title 5, U.S. Code 552b(c)(6), the Assistant Secretary for Health has made a formal determination that these latter sessions will be closed because the discussions are likely to reveal personal information concerning individuals associated with the applications. This information is exempt from mandatory disclosure.

Anyone wishing to obtain a Roster of Members, Minutes of Meeting, or other relevant information should contact Dr. Alan E. Mayers, National Center for Health Services Research and Health Care Technology Assessment, Stop 152, Park Building, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone (301) 443–3091.

* * * * *

Name: Health Services Research Review Subcommittee.

Date and time: June 12–13, 1985, 8:00 a.m.

Place: Hyatt Regency O'Hare, Ozark A Room, 9300 West Bryn Mawr Avenue, Rosemont, Illinois 60018.

Open June 12, 8:00 a.m. to 9:00 a.m.

Closed for remainder of meeting.

Purpose: The Subcommittee is charged with the initial review of grant applications for Federal assistance in the program areas administered by the National Center for Health Service Research and Health Care Technology Assessment (NCHSR).

Agenda: The open session of the meeting on June 12 from 8:00 AM to 9:00 AM will be devoted to a business meeting covering administration and reports. There will also be a presentation by the Director, NCHSR. During the closed sessions, the Subcommittee will be reviewing research grant applications relating to the delivery, organization, and financing of health services. In accordance with the Federal Advisory Committee Act, Title 5, U.S. Code, Appendix 2 and Title 5, U.S. Code 552b(c)(6), the Assistant Secretary for Health has made a formal determination that these latter sessions will be closed because the discussions are likely to reveal personal information concerning individuals associated with the applications. This informtion is exempt from mandatory disclosure.

Anyone wishing to obtain a Roster of Members, Minutes of Meeting, or other relevant information should contact Dr. Anthony Pollitt, National Center for Health Services Research and Health Care Technology Assessment, Stop 152, Park Building, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone (301) 443–3091.

Agenda items are subject to change as priorities dictate.

Dated: May 9, 1985.

John E. Marshall,

Director National Center for Health Services Research and Health Care Technology Assessment.

[FR Doc. 85–11969 Filed 5–16–85; 8:45 am]

BILLING CODE 4160–17–M

Food and Drug Administration

Immunology Devices Panel; Advisory Committee; Meeting

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meetings and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

Meeting: The following advisory committee meeting is announced:

Immunology Devices Panel

Date, time, and place. June 17 and 18, 9 a.m., Rm. 703–727A, 200 Independence Ave. SW., Washington, D.C.

Type of meeting and executive secretary. Open public hearing, June 17, 9 a.m. to 10 a.m.; open committee discussion, 10 a.m. to 12 m.; closed presentation of data, 1 p.m. to 3 p.m.; closed committee deliberations, 3 p.m. to 5 p.m.; open committee discussion, June 18, 9 a.m. to 10 a.m.; closed presentation of data, 10 a.m. to 12 m.; closed committee deliberations, 1 p.m. to 3 p.m.; open committee discussion, 3 p.m. to 5 p.m.; Srikrishna Vadlamudi, Center for Devices and Radiological Health (HFZ–440), Food and Drug Administration, 8757 Georgia Ave., Silver Spring, MD 20910, 301–427–7550.

General function of the committee. The committee reviews and evaluates available data on the safety and effectiveness of devices and makes recommendations for their regulation.

Agenda—Open public hearing. Interested persons may present data, information, or views orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the executive secretary before June 7, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open committee discussion. The committee will discuss premarket approval applications for tumor marker in vitro diagnostic assays; there will also be a general discussion of in vitro allergy testing on June 18.

Closed presentation of data/closed committee deliberations. The committee will review and discuss trade secret or confidential commercial information

regarding premarket approval applications for tumor marker in vitro diagnostic assays. These portions of the meeting will be closed to permit discussion of this information (5 U.S.C. 552b(c)(4)).

Each public advisory committee meeting listed above may have as many as four separable portions: (1) An open public hearing, (2) an open committee discussion, (3) a closed presentation of data, and (4) a closed committee deliberation. Every advisory committee meeting shall have an open public hearing portion. Whether or not it also includes any of the other three portions will depend upon the specific meeting involved. The dates and times reserved for the separate portions of each committee meeting are listed above.

The open public hearing portion of each meeting shall be at least 1 hour long unless public participation does not last that long. It is emphasized, however, that the 1 hour time limit for an open public hearing represents a minimum rather than a maximum time for public participation, and an open public hearing may last for whatever longer period the committee chairman determines will facilitate the committee's work.

Public hearings are subject to FDA's guideline concerning the policy and procedures for electronic media coverage of FDA's public administrative proceedings. This guideline was published in the **Federal Register** of April 13, 1984 (49 FR 14723). These procedures are primarily intended to expedite media access to FDA's public proceedings, including hearings before a public advisory committee conducted pursuant to Part 14 of the agency's regulations. Under this guideline, representatives of the electronic media may be permitted, subject to certain limitations, to videotape, film, or otherwise record FDA's public administrative proceedings, including the presentation of participants at a public hearing. Accordingly, all interested persons are directed to the guideline, as well as the Federal Regiser notice announcing issuance of the guideline, for a more complete explanation of the guideline's effect on public hearings.

Meetings of advisory committees shall be conducted, insofar as is practical, in accordance with the agenda published in this **Federal Register** notice. Changes in the agenda will be announced at the beginning of the open portion of a meeting.

Any interested person who wishes to be assured of the right to make an oral presentation at the open pulic hearing portion of a meeting shall inform the contact person listed above, either orally or in writing, prior to the meeting. Any person attending the hearing who does not in advance of the meeting request an opportunity to speak will be allowed to make an oral presentation at the hearing's conclusion, if time permits, at the chairman's discretion.

Persons interested in specific agenda items to be discussed in open session may ascertain from the contact person the approximate time of discussion.

A list of committee members and summary minutes of meetings may be requested from the Dockets Management Branch (HFA–305), Rm. 4–62, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, between 9 a.m. and 4 p.m., Monday through Friday.

The Commissioner, with the concurrence of the Chief Counsel, has determined for the reasons stated that those portions of the advisory committee meetings so designated in this notice shall be closed. The Federal Advisory Committee Act (FACA), as amended by the Government in the Sunshine Act (Pub. L. 94–409), permits such closed advisory committee meetings in certain circumstances. Those portions of a meeting designated as closed, however, shall be closed for the shortest possible time, consistent with the intent of the cited statutes.

The FACA, as amended, provides that a portion of a meeting may be closed where the matter for discussion involves a trade secret; commercial or financial information that is privileged or confidential; information of a personal nature, disclosure of which would be a clearly unwarranted invasion of personal privacy; investigatory files compiled for law enforcement purposes; information the premature disclosure of which would be likely to significantly frustrate implementation of a proposed agency action; and information in certain other instances not generally relevant to FDA matters.

Examples of portions of FDA advisory committee meetings that ordinarily may be closed, where necessary and in accordance with FACA criteria, include the review, discussion, and evaluation of drafts of regulations or guidelines or similar preexisting internal agency documents, but only if their premature disclosure is likely to significantly frustrate implementation of proposed agency action; review of trade secrets and confidential commercial or financial information submitted to the agency; consideration of matters involving investigatory files compiled for law enforcement purposes; and review of matters, such as personnel records or individual patient records, where disclosure would constitute a clearly unwarranted invasion of personal privacy.

Examples of portions of FDA advisory committee meetings that ordinarily shall not be closed include the review, discussion, and evaluation of general preclinical and clinical test protocols and procedures for a class of drugs or devices; consideration of labeling requirements for a class of marketed drugs or devices; review of data and information on specific investigational or marketed drugs and devices that have previously been made public; presentation of any other data or information that is not exempt from public disclosure pursuant to the FACA, as amended; and, notably deliberative sessions to formulate advice and recommendations to the agency on matters that do not independently justify closing.

This notice is issued under section 10(a) (1) and (2) of the Federal Advisory Committee Act (Pub. L. 92–463, 86 Stat. 770–776 (5 U.S.C. App. I)), and FDA's regulations (21 CFR Part 14) on advisory committees.

Dated: May 10, 1985.

Joseph P. Hile,

Acting Commissioner of Food and Drugs.

[FR Doc. 85–11929 Filed 5–16–85; 8:45 am]

BILLING CODE 4160–01–M

[Docket No. 85F–0188]

Calgon Corp.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Calgon Corp. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of acrylic acid/2-acrylamido-2-methyl propane sulfonic acid for use as a boiler water additive.

FOR FURTHER INFORMATION CONTACT: Andrew D. Laumbach, Center for Food Safety and Applied Nutrition (HFF–334), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–472–5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 5A3857) has been filed by Calgon Corp., Calgon Center, Box 1346, Pittsburgh, PA 15230, proposing that Part 173 (21 CFR Part 173) be amended to provide for the safe use of acrylic acid/

2-acrylamido-2-methyl propane sulfonic acid for use as a boiler water additive.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c) (proposed December 11, 1979; 44 FR 71742).

Dated: May 8, 1985.

Richard J. Ronk,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 85-11926 Filed 5-16-85; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 85F-0183]

General Electric Co.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that General Electric Co. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of hydrogen peroxide for sterilizing food-contact surfaces prepared from polycarbonate resins.

FOR FURTHER INFORMATION CONTACT: Blondell Anderson, Center for Food Safety and Applied Nutrition (HFF-334), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5740.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 5B3858) has been filed by General Electric Co., Highway 69 South, Mt. Vernon, IN 47620, proposing that § 178.1005 of the food additive regulations (21 CFR 178.1005) be amended to provide for the safe use of hydrogen peroxide for sterilizing food-contact surfaces prepared from polycarbonate resins.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c) (proposed December 11, 1979; 44 FR 71742).

Dated: May 8, 1985.

Richard J. Ronk,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 85-11924 Filed 5-16-85; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 84F-0317]

McCormick & Co., Inc.; Amended Notice of Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is amending a notice that announced that McCormick & Co., Inc., had filed a petition proposing that the food additive regulations be amended to provide for the safe use of a source of gamma radiation to control insect and microbial contamination in certain dried spices and dried vegetable seasonings at doses not to exceed 3 megarads (3 Mrad). This notice is amended to increase the list of permitted spices and seasonings as well as to increase the maximum permitted dose from 1 to 3 Mrad.

FOR FURTHER INFORMATION CONTACT: Clyde A. Takeguchi, Center for Food Safety and Applied Nutrition (HFF-334), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of October 9, 1984 (49 FR 39615), FDA announced that a petition (FAP 4M3816) had been filed by McCormick & Co., Inc., 11350 McCormick Rd., Hunt Valley, MD 21031-1066, proposing that Part 179 (21 CFR Part 179) be amended to provide for the safe use of a cobalt-60 or cesium-137 source of gamma radiation to control insect and microbial infestation in certain dried spices and dried vegetable seasonings by increasing the maximum permitted dose from 1 to 3 Mrad.

On November 14, 1983, a citizen petition (83P-0386/CP), filed by McCormick & Co., Inc., requested amendment of the regulations to provide for the safe use of gamma radiation for the treatment of substances listed in § 182.10 *Spices and other natural seasonings and flavorings* (21 CFR 182.10), dehydrated onion products, dehydrated garlic products, and other natural substances used as minor ingredients solely for their flavoring properties; and blends representing any combination of said substances at an absorbed dose not to exceed 30 kiloGray (3.0 Mrad). The petitioner further stated that the qualifying phrase "minor ingredients used solely for their flavoring properties" includes the smaller particle sizes of dehydrated or dried products. This excludes the larger particle sizes used for purposes other than flavoring, e.g., as vegetables.

The petitioner has withdrawn its citizen petition and resubmitted it as an amendment to food additive petition (FAP 4M3816).

Dated: May 8, 1985.

Richard J. Ronk,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 85-11925 Filed 5-16-85; 8:45 am]

BILLING CODE 4160-01-M

[FDA-225-85-6000]

Memorandum of Understanding With the National Cancer Institute

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) has executed a memorandum of understanding with the National Cancer Institute (NCI). The agreement, between NCI's Radiation Epidemiology Branch and FDA's Center for Devices and Radiological Health, is to facilitate a study of subsequent cancer incidence in women treated by irradiation with x-rays for infertility.

DATE: This agreement became effective April 10, 1985.

FOR FURTHER INFORMATION CONTACT: Walter J. Kustka, Intergovernmental and Industry Affairs Staff (HFC-50), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-1583.

SUPPLEMENTARY INFORMATION: In accordance with § 20.108(c) (21 CFR 20.108(c)) which states that all agreements and memoranda of understanding between FDA and others shall be published in the **Federal Register**, the agency is publishing the following memorandum of understanding:

Memorandum of Understanding Between the National Cancer Institute and the Food and Drug Administration

I. Purpose

This agreement between the Radiation Epidemiology Branch of the National Cancer Institute (NCI) and the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) is to facilitate a study of subsequent cancer incidence in women treated by irradiation with x-rays for infertility.